Clinical Trials Browser

Urinary Bladder Neoplasms

NCT04887831 2025-09-08

PRESERVE3

Phase 2 Terminated

92 enrolled 24 charts

Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT05007106 2025-08-14

KEYVIBE-005

Phase 2 Completed

613 enrolled

BreastGastrointestinalGenitourinaryGynecologicHead & Neck

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma, Triple Negative Breast Neoplasms

NCT05312671 2025-06-29

Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer

Phase 2 Recruiting

63 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT04871529 2024-12-30

Testing the Addition of an Anti-Cancer Immunotherapy Drug, Avelumab, to Gemcitabine and Carboplatin Chemotherapy Prior to Surgery in Muscle Invasive Urinary Tract Cancer vs. Surgery Alone in Patients Who Are Not Able to Receive Cisplatin Therapy (SWOG GAP TRIAL)

Phase 2 Terminated

6 enrolled 12 charts

Genitourinary

Urinary Bladder Neoplasms

NCT03520231 2021-11-23

Study Comparing Denosumab With Standard Treatment in Urothelial Cancer Patients With Bone Metastases

Phase 2 Completed

6 enrolled

Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Kidney Neoplasms, Ureteral Neoplasms

NCT02665039 2019-10-08

VINGEM

Phase 2 Completed

62 enrolled

Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms

NCT01191892 2019-05-16

Carboplatin and Gemcitabine Hydrochloride With or Without Vandetanib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Urinary Tract Cancer

Phase 2 Completed

82 enrolled

Genitourinary

Urinary Bladder Neoplasms, Ureteral Neoplasms, Urethral Neoplasms

NCT00461851 2017-12-14

Trial of Gemcitabine, Carboplatin, and Sorafenib in Chemotherapy-naive Patients With Advanced/Metastatic Bladder Carcinoma

Phase 2 Completed

17 enrolled 10 charts

Genitourinary

Urinary Bladder Neoplasms

NCT01828736 2017-02-06

CVH-CT02

Phase 2 Completed

61 enrolled

Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT00003657 2017-01-20

High-dose ICE With Amifostine

Phase 2 Completed

24 enrolled

CNSGenitourinaryGynecologicHead & NeckSarcomaThoracic

AIDS-related Kaposi sarcoma, Testicular Germ Cell Tumor, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Ovarian Epithelial, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Chondrosarcoma, Head and Neck Neoplasms, Kidney Neoplasms, Lung Neoplasms, Neoplasms, Unknown Primary, Ovarian Neoplasms, Sarcoma, Sarcoma, Kaposi, Osteosarcoma, Testicular Neoplasms, Central Nervous System Neoplasms, Neuroectodermal Tumors, Primitive, Peripheral, Esthesioneuroblastoma, Olfactory, Small Cell Lung Carcinoma

NCT01454089 2016-10-07

A Phase 2 Study Comparing Chemotherapy in Combination With OGX-427 or Placebo in Patients With Bladder Cancer

Phase 2 Completed

183 enrolled

Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Urologic Neoplasms

NCT01916109 2016-02-12

Study of Gemcitabine, Carboplatin, and Panitumumab (GCaP) as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer

Phase 2 Terminated

4 enrolled 6 charts

Genitourinary

Cone Dystrophy 3, Urinary Bladder Neoplasms

NCT01599013 2015-12-08

JASINT1

Phase 2 Completed

69 enrolled

Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Neoplasm Metastasis, Urogenital Neoplasms, Urologic Neoplasms, Renal Insufficiency

NCT00585689 2015-11-30

Neoadjuvant ABI-007, Carboplatin and Gemcitabine in Locally Advanced Bladder Cancer

Phase 2 Completed

29 enrolled 11 charts

Genitourinary

Urinary Bladder Neoplasms

NCT00136175 2015-01-21

Paclitaxel, Carboplatin and Gemcitabine in the Treatment of Patients With Advanced Transitional Cell Cancer of the Bladder

Phase 2 Completed

68 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT00028860 2013-07-10

Combination Chemotherapy Following Surgery in Treating Patients With Urinary Tract Cancer

Phase 2 Completed

Genitourinary

Urinary Bladder Neoplasms

NCT00045630 2013-05-27

S0219, Combination Chemotherapy Followed By Observation or Surgery in Patients With Stage II or Stage III Cancer of the Urothelium

Phase 2 Completed

77 enrolled 11 charts

Genitourinary

Urinary Bladder Neoplasms, Urethral Neoplasms

NCT00055835 2013-01-31

S0121, Neoadjuvant Carboplatin, Paclitaxel, and Gemcitabine Followed by Cisplatin and Radiation Therapy in Treating Patients With Locally Advanced or Recurrent Carcinoma of the Urothelium

Phase 2 Completed

7 enrolled

Genitourinary

Urinary Bladder Neoplasms, Urethral Neoplasms

NCT00005831 2013-01-14

Trastuzumab and Combination Chemotherapy in Treating Patients With Locally Recurrent or Metastatic Urinary Tract Cancer

Phase 2 Completed

40 enrolled

Genitourinary

Urinary Bladder Neoplasms

Clinical Trials

BCIRT-01

PRESERVE3

KEYVIBE-005

Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer

Testing the Addition of an Anti-Cancer Immunotherapy Drug, Avelumab, to Gemcitabine and Carboplatin Chemotherapy Prior to Surgery in Muscle Invasive Urinary Tract Cancer vs. Surgery Alone in Patients Who Are Not Able to Receive Cisplatin Therapy (SWOG GAP TRIAL)

Study Comparing Denosumab With Standard Treatment in Urothelial Cancer Patients With Bone Metastases

VINGEM

Carboplatin and Gemcitabine Hydrochloride With or Without Vandetanib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Urinary Tract Cancer

Trial of Gemcitabine, Carboplatin, and Sorafenib in Chemotherapy-naive Patients With Advanced/Metastatic Bladder Carcinoma

CVH-CT02

High-dose ICE With Amifostine

A Phase 2 Study Comparing Chemotherapy in Combination With OGX-427 or Placebo in Patients With Bladder Cancer

Study of Gemcitabine, Carboplatin, and Panitumumab (GCaP) as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer

JASINT1

Neoadjuvant ABI-007, Carboplatin and Gemcitabine in Locally Advanced Bladder Cancer

Paclitaxel, Carboplatin and Gemcitabine in the Treatment of Patients With Advanced Transitional Cell Cancer of the Bladder

Combination Chemotherapy Following Surgery in Treating Patients With Urinary Tract Cancer

S0219, Combination Chemotherapy Followed By Observation or Surgery in Patients With Stage II or Stage III Cancer of the Urothelium

S0121, Neoadjuvant Carboplatin, Paclitaxel, and Gemcitabine Followed by Cisplatin and Radiation Therapy in Treating Patients With Locally Advanced or Recurrent Carcinoma of the Urothelium

Trastuzumab and Combination Chemotherapy in Treating Patients With Locally Recurrent or Metastatic Urinary Tract Cancer